@chaelinkim.bsky.social
Reposted
Our framework that informed the @who.int TB & climate change policy brief out now in @lancetrespirmed.bsky.social, exploring the intersections and implications of climate change for the TB epidemic. Key message? TB should be considered a climate-sensitive disease
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Climate change and tuberculosis: an analytical framework
Climate change is likely to exacerbate a range of determinants that drive tuberculosis,
the world's leading cause of death from a single infectious agent. However, tuberculosis
is often neglected in w...
www.thelancet.com
October 31, 2025 at 9:12 AM
Our framework that informed the @who.int TB & climate change policy brief out now in @lancetrespirmed.bsky.social, exploring the intersections and implications of climate change for the TB epidemic. Key message? TB should be considered a climate-sensitive disease
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Reposted
Reflecting on this year’s #TB #UnionConf2024 and am so inspired by the brilliant minds and groundbreaking research being done to combat this global health threat. Special shoutout to the TB Modelling Group @lshtm.bsky.social 🫁
November 17, 2024 at 7:56 PM
Reflecting on this year’s #TB #UnionConf2024 and am so inspired by the brilliant minds and groundbreaking research being done to combat this global health threat. Special shoutout to the TB Modelling Group @lshtm.bsky.social 🫁
When fluoroquinolone resistance status is unknown, empirical use of BPaLM (adding moxifloxacin to BPaL) is cost-effective as a replacement for BPaL even with high fluoroquinolone resistance levels! 🦠💊
doi.org/10.1371/jour...
doi.org/10.1371/jour...
Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis
The WHO recommends the bedaquiline, pretomanid, and linezolid (BPaL) regimen with the additional fluoroquinolone antibiotic moxifloxacin (BPaLM) for initial treatment of multidrug- or rifampicin-resis...
doi.org
October 20, 2025 at 6:47 PM
When fluoroquinolone resistance status is unknown, empirical use of BPaLM (adding moxifloxacin to BPaL) is cost-effective as a replacement for BPaL even with high fluoroquinolone resistance levels! 🦠💊
doi.org/10.1371/jour...
doi.org/10.1371/jour...